Clinical utility of thrombophilia, anticoagulant treatment, and maternal variables as predictors of placenta-mediated pregnancy complications: an extensive analysis

References

• Rodger MA, Langlois NJ, Vries JIPd, et al. Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM). Syst Res. 2014;3:69.
   Google Scholar
• Rodger MA. An update on thrombophilia and placenta mediated pregnancy complications: what should we tell our patients? Thromb Res. 2013;131:S25–S27.
   PubMed Web of Science ®Google Scholar
• Kovo M, Schreiber L, Bar J. Placental vascular pathology as a mechanism of disease in pregnancy complications. Thromb Res. 2013;131:S18–S21.
   PubMed Web of Science ®Google Scholar
• Su MT, Lin SH, Chen YC, et al. Genetic association studies of ACE and PAI-1 genes in women with recurrent pregnancy loss: a systematic review and meta-analysis. Thromb Haemost. 2013;109:8–15.
   PubMed Web of Science ®Google Scholar
• Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess. 2006;10:1–110.
   PubMed Web of Science ®Google Scholar
• Tuuli MG, Odibo AO. The role of serum markers and uterine artery Doppler in identifying at-risk pregnancies. Clin Perinatol. 2011;38:1–19.
   PubMed Web of Science ®Google Scholar
• Rodger MA. Anticoagulant prophylaxis for placenta mediated pregnancy complications. Thromb Res. 2011;127:S76–S80.
   PubMed Web of Science ®Google Scholar
• Kurasawa G, Kotani K, Ito Y, et al. Reduction in protein S activity during normal pregnancy. Aust N Z J Obstet Gynaecol. 2007;47:213–215.
   PubMed Web of Science ®Google Scholar
• RCOG. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. UK: Royal College of Obstetricians and Gynaecologists; 2015. (Green-top Guideline No. 37a).
   Google Scholar
• Dodd JM, McLeod A, Windrim RC, et al. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev. 2013;7:CD006780.
   PubMed Web of Science ®Google Scholar
• de Jong PG, Kaandorp S, Di Nisio M, et al. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev. 2014;7:CD004734.
   PubMed Web of Science ®Google Scholar
• Borque Á, Rubio-Briones J, Esteban LM, et al. Implementing the use of nomograms by choosing threshold points in predictive models: 2012 updated Partin tables vs a European predictive nomogram for organ-confined disease in prostate cancer. BJU Int. 2014;113:878–886.
   PubMed Web of Science ®Google Scholar
• Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med. 1996;15:361–387.
   PubMed Web of Science ®Google Scholar
• Borque-Fernando Á, Esteban-Escaño LM, Rubio-Briones J, et al. A preliminary study of the ability of the 4Kscore test, the prostate cancer prevention trial-risk calculator and the European research screening prostate-risk calculator for predicting high-grade prostate cancer. Actas Urol Esp. 2016;40:155–163.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016. Available from: http://www.R-project.org/
   Google Scholar
• Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132:171–196.
   PubMed Web of Science ®Google Scholar
• Lykke JA, Bare LA, Olsen J, et al. Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. J Thromb Haemost. 2012;10:1320–1325.
   PubMed Web of Science ®Google Scholar
• Salafia CM, Pezzullo JC, López-Zeno JA, et al. Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol. 1995;173:1097–1105.
   PubMed Web of Science ®Google Scholar
• D’Ippolito S, Ortiz AS, Veglia M, et al. Low molecular weight heparin in obstetric care: a review of the literature. Reprod Sci. 2011;18:602–613.
   PubMed Web of Science ®Google Scholar
• Johnson J, Clifton RG, Roberts JM, et al. Pregnancy outcomes with weight gain above or below the 2009 Institute of Medicine guidelines. Obstet Gynecol. 2013;121:969–975.
   PubMed Web of Science ®Google Scholar
• Viswanathan M, Siega-Riz AM, Moos MK, et al. Outcomes of maternal weight gain. Evid Rep Technol Assess (Full Rep). 2008;1:1–223.
   Google Scholar
• Institute of Medicine and National Research Council. 2009. Weight gain during pregnancy: reexamining the guidelines. Washington (DC): The National Academies Press. Available from: https://doi.org/10.17226/12584
   Google Scholar
• Østensen M, Andreoli L, Brucato A, et al. State of the art: reproduction and pregnancy in rheumatic diseases. Autoimmun Rev. 2015;14:376–386.
   PubMed Web of Science ®Google Scholar
• Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta- analysis. Obstet Gynecol. 2010;116:402–414.
   PubMed Web of Science ®Google Scholar
• Scioscia M, Nigro M, Montagnani M. The putative metabolic role of d-chiro inositol phosphoglycan in human pregnancy and preeclampsia. J Reprod Immunol. Review. 2014;101–102;140–147.
   PubMed Web of Science ®Google Scholar
• Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e691S–e736S.
   PubMed Web of Science ®Google Scholar
• Howley HA. Systematic review: FVL or PGM and IUGR. Am J Obstet Gynecol. 1998;179:1565–1567.
   PubMed Web of Science ®Google Scholar
• Rath W. Pre-eclampsia and inherited thrombophilia: a reappraisal. Semin Thromb Hemost. 2011;37:118–124.
   PubMed Web of Science ®Google Scholar
• Infante-Rivard C, Rivard GE, Yotov WV, et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med. 2002;347:19–25.
   PubMed Web of Science ®Google Scholar
• SOGC Clinical Practice Guideline. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can. 2014;36:527–553.
   PubMedGoogle Scholar
• Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al. Comparative incidence of pregnancy outcomes in thrombophilia-positive women from the NOH-APS observational study. Blood. 2014;123:414–421.
   PubMed Web of Science ®Google Scholar
• Rodger MA, Walker MC, Smith GN, et al. Is thrombophilia associated with placenta-mediated pregnancycomplications? A prospective cohort study. J Thromb Haemost. 2014;12:469–478.
   PubMed Web of Science ®Google Scholar
• Rodger MA, Carrier M, Le Gal G, et al. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood. 2014;123:822–828.
   PubMed Web of Science ®Google Scholar
• Mastrolia SA, Mazor M, Holcberg G, et al. The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications. Thromb Haemost. 2015;113:1236–1246.
   PubMed Web of Science ®Google Scholar
• Mutlu I, Mutlu MF, Biri A, et al. Effects of anticoagulant therapy on pregnancy outcomes in patients with thrombophilia and previous poor obstetric history. Blood Coagul Fibrinolysis. 2015;26:267–273.
   PubMed Web of Science ®Google Scholar
• Quaranta M, Erez O, Mastrolia SA, et al. The physiologic and therapeutic role of heparin in implantation and placentation. PeerJ. 2015;3:6e691.
   Web of Science ®Google Scholar